Pharmacotherapy in Medicare beneficiaries with atrial fibrillation

Heart Rhythm

Volumn 9, Issue 9, 2012, Pages 1403-1408

  Piccini, Jonathan P ^a,b   Mi, Xiaojuan ^a   Dewald, Tracy A ^b   Go, Alan S ^c,d   Hernandez, Adrian F ^a,b   Curtis, Lesley H ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DIVISION OF RESEARCH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adrenergic beta antagonists; Antiarrhythmia agents; Anticoagulants; Atrial fibrillation; Calcium channel blockers; drug therapy

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CLOPIDOGREL; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; DOFETILIDE; ENOXAPARIN; FLECAINIDE; METOPROLOL; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; VERAPAMIL; WARFARIN;

AGED; ARTICLE; BILLING AND CLAIMS; CARDIOVASCULAR RISK; COMORBIDITY; COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CALCIUM CHANNEL BLOCKERS; FEMALE; HEART RATE; HUMANS; MALE; MEDICARE PART D; PREVALENCE; UNITED STATES;

EID: 84865636427     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2012.04.031     Document Type: Article

References (23)

1. P.A. Wolf, E.J. Benjamin, A.J. Belanger, W.B. Kannel, D. Levy, R.B. D'Agostino Secular trends in the prevalence of atrial fibrillation: the Framingham Study Am Heart J 131 1996 790 795
2. E.J. Benjamin, D. Levy, S.M. Vaziri, R.B. D'Agostino, A.J. Belanger, P.A. Wolf Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study JAMA 271 1994 840 844
3. S.J. Connolly, J. Eikelboom, C. Joyner Apixaban in patients with atrial fibrillation N Engl J Med 364 2011 806 817
4. Institute of Medicine Initial National Priorities for Comparative Effectiveness Research 2009 Institute of Medicine Washington, DC
5. J.P. Piccini, R.D. Lopes, M.H. Kong, V. Hasselblad, K. Jackson, S.M. Al-Khatib Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta-analysis of randomized, controlled trials Circ Arrhythm Electrophysiol 2 2009 626 633
6. J.P. Piccini, R.D. Lopes, K.W. Mahaffey Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation Curr Opin Cardiol 25 2010 312 320
7. Centers for Medicare & Medicaid Services Part D claims data https://www.cms.gov/Medicare/Prescription-Drug-Coverage/ PrescriptionDrugCovGenIn/PartDData.html Accessed April 6, 2012
8. E. Birman-Deych, A.D. Waterman, Y. Yan, D.S. Nilasena, M.J. Radford, B.F. Gage Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors Med Care 43 2005 480 485
9. H. Quan, V. Sundararajan, P. Halfon Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data Med Care 43 2005 1130 1139
10. B.F. Gage, A.D. Waterman, W. Shannon, M. Boechler, M.W. Rich, M.J. Radford Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
11. L.S. Wann, A.B. Curtis, C.T. January 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 123 2011 104 123
12. M.H. Kim, S.S. Johnston, B.C. Chu, M.R. Dalal, K.L. Schulman Estimation of total incremental health care costs in patients with atrial fibrillation in the United States Circ Cardiovasc Qual Outcomes 4 2011 313 320
13. European Heart Rhythm Association; Heart Rhythm Society V. Fuster ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillationexecutive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) J Am Coll Cardiol 48 2006 854 906
14. J.Y. Le Heuzey, G. Breithardt, J. Camm The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation Am J Cardiol 105 2010 687 693
15. R. Nieuwlaat, A. Capucci, A.J. Camm Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation Eur Heart J 26 2005 2422 2434
16. J.W. Mason Amiodarone N Engl J Med 316 1987 455 466
17. J.P. Piccini, V. Hasselblad, E.D. Peterson, J.B. Washam, R.M. Califf, D.F. Kong Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation J Am Coll Cardiol 54 2009 1089 1095
18. J.P. Piccini, D.F. Kong Mixed treatment comparisons for atrial fibrillation: evidence network or bewildering entanglement? Europace 13 2011 295 296
19. E. Birman-Deych, M.J. Radford, D.S. Nilasena, B.F. Gage Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation Stroke 37 2006 1070 1074
20. A.S. Go, E.M. Hylek, L.H. Borowsky, K.A. Phillips, J.V. Selby, D.E. Singer Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study Ann Intern Med 131 1999 927 934
21. R.K. Sandhu, J.A. Bakal, J.A. Ezekowitz, F.A. McAlister Risk stratification schemes, anticoagulation use and outcomes: the risktreatment paradox in patients with newly diagnosed non-valvular atrial fibrillation Heart 97 2011 2046 2050
22. ACTIVE Writing Group of the ACTIVE Investigators S. Connolly, J. Pogue Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 2006 1903 1912
23. R.A. Kokotailo, M.D. Hill Coding of stroke and stroke risk factors using International Classification of Diseases, Revisions 9 and 10 Stroke 36 2005 1776 1781